Pharma major Dr Reddy's Laboratories Ltd has received approval from the US Food and Drug Administration (US FDA) for ZEMBRACE SymTouch (sumatriptan succinate) injection, a drug-device combination product intended for the treatment of acute migraine in adults.
It is available as a prefilled, ready-to-use, single dose disposable auto injector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. The injection is intended to be given subcutaneously.
“ZEMBRACESymTouch is specifically designed for patients who may experience certain migraine episodes and for whom a pill may not be the right option,’’ Raghav Chari, Executive Vice-President, Proprietary Products Group, Dr Reddy’s, said in a release issued here on Friday.
Post a Comment